223 related articles for article (PubMed ID: 16052085)
1. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
3. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group.
Anglaret X; Chêne G; Attia A; Toure S; Lafont S; Combe P; Manlan K; N'Dri-Yoman T; Salamon R
Lancet; 1999 May; 353(9163):1463-8. PubMed ID: 10232311
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial.
Wiktor SZ; Sassan-Morokro M; Grant AD; Abouya L; Karon JM; Maurice C; Djomand G; Ackah A; Domoua K; Kadio A; Yapi A; Combe P; Tossou O; Roels TH; Lackritz EM; Coulibaly D; De Cock KM; Coulibaly IM; Greenberg AE
Lancet; 1999 May; 353(9163):1469-75. PubMed ID: 10232312
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
6. Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Côte d'Ivoire.
Castetbon K; Anglaret X; Attia A; Toure S; Dakoury-Dogbo N; Messou E; N'Dri-Yoman T; Dabis F; Salamon R;
AIDS; 2001 May; 15(7):869-76. PubMed ID: 11399959
[TBL] [Abstract][Full Text] [Related]
7. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations.
Badri M; Ehrlich R; Wood R; Maartens G
AIDS; 2001 Jun; 15(9):1143-8. PubMed ID: 11416716
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
[TBL] [Abstract][Full Text] [Related]
9. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda.
Pitter C; Kahn JG; Marseille E; Lule JR; McFarland DA; Ekwaru JP; Bunnell R; Coutinho A; Mermin J
J Acquir Immune Defic Syndr; 2007 Mar; 44(3):336-43. PubMed ID: 17327758
[TBL] [Abstract][Full Text] [Related]
11. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
Walker AS; Ford D; Gilks CF; Munderi P; Ssali F; Reid A; Katabira E; Grosskurth H; Mugyenyi P; Hakim J; Darbyshire JH; Gibb DM; Babiker AG
Lancet; 2010 Apr; 375(9722):1278-86. PubMed ID: 20347483
[TBL] [Abstract][Full Text] [Related]
12. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.
Freedberg KA; Hardy WD; Holzman RS; Tosteson AN; Craven DE
Med Decis Making; 1996; 16(1):29-35. PubMed ID: 8717596
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings.
Dugdale CM; Ufio O; Alba C; Permar SR; Stranix-Chibanda L; Cunningham CK; Fouda GG; Myer L; Weinstein MC; Leroy V; McFarland EJ; Freedberg KA; Ciaranello AL
J Int AIDS Soc; 2023 Jan; 26(1):e26052. PubMed ID: 36604316
[TBL] [Abstract][Full Text] [Related]
14. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.
Losina E; Yazdanpanah Y; Deuffic-Burban S; Wang B; Wolf LL; Messou E; Gabillard D; Seyler C; Freedberg KA; Anglaret X
Antivir Ther; 2007; 12(4):543-51. PubMed ID: 17668563
[TBL] [Abstract][Full Text] [Related]
15. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.
Suthar AB; Vitoria MA; Nagata JM; Anglaret X; Mbori-Ngacha D; Sued O; Kaplan JE; Doherty MC
Lancet HIV; 2015 Apr; 2(4):e137-50. PubMed ID: 26424674
[TBL] [Abstract][Full Text] [Related]
16. Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Côte d'Ivoire.
Toure S; Gabillard D; Inwoley A; Seyler C; Gourvellec G; Anglaret X
Trans R Soc Trop Med Hyg; 2006 Aug; 100(8):785-90. PubMed ID: 16458337
[TBL] [Abstract][Full Text] [Related]
17. Improved survival with co-trimoxazole prophylaxis among people living with HIV/AIDS who initiated antiretroviral treatment in Henan Province, China.
Zhu Q; Wang L; Lin W; Bulterys M; Yang W; Sun D; Cui Z; Kaplan J; Kleinman N; Wei X; Chung J; Wang Z
Curr HIV Res; 2014; 12(5):359-65. PubMed ID: 25426939
[TBL] [Abstract][Full Text] [Related]
18. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.
Mermin J; Lule J; Ekwaru JP; Malamba S; Downing R; Ransom R; Kaharuza F; Culver D; Kizito F; Bunnell R; Kigozi A; Nakanjako D; Wafula W; Quick R
Lancet; 2004 Oct 16-22; 364(9443):1428-34. PubMed ID: 15488218
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
Crook AM; Turkova A; Musiime V; Bwakura-Dangarembizi M; Bakeera-Kitaka S; Nahirya-Ntege P; Thomason M; Mugyenyi P; Musoke P; Kekitiinwa A; Munderi P; Nathoo K; Prendergast AJ; Walker AS; Gibb DM;
BMC Med; 2016 Mar; 14():50. PubMed ID: 27004529
[TBL] [Abstract][Full Text] [Related]
20. Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial.
Laurens MB; Mungwira RG; Nampota N; Nyirenda OM; Divala TH; Kanjala M; Mkandawire FA; Galileya LT; Nyangulu W; Mwinjiwa E; Downs M; Tillman A; Taylor TE; Mallewa J; Plowe CV; van Oosterhout JJ; Laufer MK
Clin Infect Dis; 2021 Sep; 73(6):1058-1065. PubMed ID: 33744963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
